| Completed | Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Su Drug Interactions | Phase 1 | 2023-01-03 |
| Completed | Study to Evaluate the Safety, Tolerability, and PK of Pacritinib Hepatic Impairment | Phase 1 | 2022-12-12 |
| Terminated | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer COVID19, COVID-19, COVID | Phase 2 | 2020-05-22 |
| Completed | Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary My Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis | Phase 2 | 2017-07-31 |
| Withdrawn | Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer Lymphoma, Solid Tumor (Excluding CNS) | Phase 1 | 2016-10-24 |
| Completed | To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Ad Healthy | Phase 1 | 2015-08-01 |
| Completed | Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects Myelofibrosis | Phase 1 | 2015-01-01 |
| Completed | Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Soluti Healthy Subjects | Phase 1 | 2015-01-01 |
| Completed | Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure o Healthy Subjects | Phase 1 | 2015-01-01 |
| Completed | PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subject Myelofibrosis | Phase 1 | 2014-11-01 |
| Completed | To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Sub Healthy Subjects | Phase 1 | 2014-10-01 |
| Completed | To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects Drug Interaction Study | Phase 1 | 2014-09-01 |
| Completed | Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib Healthy | Phase 1 | 2014-07-01 |
| Terminated | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 3 | 2014-02-01 |
| Terminated | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 3 | 2013-01-01 |
| Completed | Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects Healthy | Phase 1 | 2012-06-01 |
| Withdrawn | Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment Metastatic Cancer | Phase 1 | 2012-05-01 |
| Completed | Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgk Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma | Phase 3 | 2011-04-20 |
| Withdrawn | Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL Non-Hodgkin's Lymphoma | Phase 3 | 2007-09-01 |
| Withdrawn | CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL NSCLC | Phase 3 | 2007-09-01 |
| Terminated | Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Re Lung Cancer | Phase 3 | 2007-08-01 |
| Withdrawn | Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Leukemia, Lymphoma | Phase 3 | 2007-08-01 |
| Terminated | A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. NSCLC | Phase 3 | 2005-12-01 |
| Completed | A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin Diffuse Large-Cell Lymphoma | Phase 2 | 2005-11-01 |
| Completed | Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) Acute Myelogenous Leukemia | Phase 1 / Phase 2 | 2005-03-01 |
| Terminated | Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma Lymphoma, Follicular, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular | Phase 3 | 2005-01-01 |
| Completed | CT-2106 for the Second Line Treatment of Ovarian Cancer Ovarian Cancer | Phase 2 | 2004-11-01 |
| Completed | BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) Lymphoma, Non-Hodgkin | Phase 3 | 2004-07-01 |
| Completed | Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer Colorectal Cancer | Phase 1 / Phase 2 | 2004-01-01 |
| Completed | Phase II CT-2103/Carboplatin in Ovarian Cancer Ovarian Neoplasm | Phase 2 | 2003-02-01 |
| Terminated | Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Lung Cancer | Phase 3 | 2003-01-01 |
| Terminated | Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurr Lung Cancer | Phase 3 | 2003-01-01 |
| Terminated | Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Can Lung Cancer | Phase 3 | 2003-01-01 |
| Completed | Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic, Lymphoma, Mixed-Cell, Follicular | Phase 1 | 2001-12-01 |
| Terminated | Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms | Phase 2 | 2001-03-01 |
| Terminated | Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Mul Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | 2001-02-01 |
| Terminated | Arsenic Trioxide in Treating Patients With Multiple Myeloma Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | 2001-01-01 |
| Terminated | CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy Prostate Cancer | Phase 2 | 1998-12-01 |